

**REMARKS**

Applicant respectfully requests the Examiner to enter the new Abstract of Disclosure and to pass pending Claims 14 to 22 to allowance. It is noted that the Examiner's Amendment to the Abstract of Disclosure present in the Notice of Allowance was not acceptable to Applicant, given the USPTO's view that the Abstract of Disclosure may be used to determine the meaning of claims (*see e.g.*, M.P.E.P. §1302.04).

**Status of Claims**

Claims 14 to 22 are pending and have been allowed.

**Amendment**

The specification is being amended to provide a new Abstract Of The Disclosure.

It is noted that the terms "inhibition" and "treatment" include in their meaning the terms "preventing" and "ameliorating". It is also respectfully submitted that the specification provides non-limiting examples of conditions arising from or associated with hyperactive gastrointestinal motility.

No new matter is added by the amendments to the specification or claims.

**CONCLUSION**

Applicant respectfully requests entry of the present Abstract of Disclosure. Early and favorable notification of allowance of all pending claims is earnestly requested.

Respectfully Submitted,




Kimberly R. Hild  
Registration No. 39,224

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No.: (484) 865-8610

(NEW)

**ABSTRACT OF THE DISCLOSURE**

This invention provides methods for the treatment or inhibition of hyperactive gastrointestinal motility in a mammal utilizing compounds having the formula:



where R, and R<sup>1</sup> to R<sup>6</sup> are described herein.